Digital pathology means scanning glass slides with tissue samples into digital pictures. Special slide scanners make these clear images. The images are stored on servers or in the cloud, and can be reached from far away. Changing from old ways to digital has some benefits:
Some companies like Grundium make slide scanners easier to get. Their Ocus® series scanners, such as Ocus 20, Ocus 40, and Ocus M, support scanning many slides quickly and help during surgeries. Grundium also offers training and cost-effective solutions for smaller labs with less money.
Even with good points, digital pathology has problems. Many advanced systems in the United States are meant only for research use, not regular patient diagnosis. This means they have not been approved yet by groups like the Food and Drug Administration (FDA) for normal clinical work.
Why is Digital Pathology Research Use Only?
Limiting use to research lets academic centers and special labs try out digital pathology tools. They can work on managing images, sharing work remotely, and creating AI models without using unapproved devices to make patient care decisions. This makes it important to separate research from clinical diagnosis in planning.
Setting up digital pathology systems takes a lot of money and building new systems. Main challenges include:
Healthcare groups wanting to use digital pathology should check if their equipment and staff are ready. They should plan how to change workflows for success.
One big new idea in digital pathology is using artificial intelligence (AI) and workflow automation. Many systems are still in research, but they might help improve accuracy, reduce work, and speed up routine tasks.
For example, PathAI has made an AI system called AISight. This AI learned from over 15 million marked images. Features include:
But AI can cause some problems. If trained on data that does not represent all patients, it can make mistakes and treat some groups unfairly. This could affect diagnoses and treatments. That is why pathologists, data experts, and ethics specialists must work together before using AI in clinics.
Using AI should be done carefully. It must be clear, fair, and checked often to keep patients safe. AI tools are there to help, not replace, human doctors.
Digital pathology helps labs work faster. This fits with U.S. medical goals to give better care quickly. Fast lab results let doctors start treatment sooner. This lowers patient stress and can improve health, especially for cancer. Better accuracy and remote teamwork also help get second opinions and special checks, raising care quality.
Switching to digital can cost a lot at first. But over time, it can make labs run better, reduce mistakes, and handle more tests.
As AI becomes more common in digital pathology, it is important to watch for bias and ethics. Experts say bias in AI can be:
U.S. pathology labs know they must check AI tools all through their development and use. Teams including data scientists, pathologists, and healthcare leaders should watch AI closely to keep it fair and open.
Understanding both what digital pathology can do and its limits helps U.S. healthcare leaders make good choices. Balancing new technology with patient safety, laws, and smooth operations is key. As these tools improve, a careful but open approach to research and use in clinics will best help medical labs provide correct and on-time diagnosis.
AISight is a cloud-based digital pathology image management system that serves as a central hub for case management, image management, and AI integration, designed to enhance digital pathology workflows.
The new features are the Intelligent Caselist and AISight Live, which aim to optimize case review, collaboration, and pathology workflows through real-time interactions and efficient case prioritization.
AISight Live includes features that facilitate real-time collaboration such as a Sync view for slide navigation and a Participants list for inviting other pathologists to consult or review cases.
The Intelligent Caselist offers a streamlined view of case workloads with filterable charts and embedded AI to assist pathologists in prioritizing cases more efficiently.
The AISight platform was developed with input from hundreds of pathologists across various institutions, ensuring it meets the real needs of its users.
PathAI’s goal is to enhance patient outcomes through AI-powered pathology solutions that streamline workflows and allow pathologists to focus on critical aspects of patient care.
AISight is currently used by leading anatomic pathology laboratories, including reference and independent laboratories as well as academic medical centers.
No, AISight is designated for research use only and is not approved for diagnostic procedures.
PathAI manages one of the country’s largest anatomic pathology labs, located in Memphis, TN, which is CAP/CLIA-certified.
PathAI aims to provide comprehensive precision pathology solutions to optimize pathology sample analysis, improve interpretation accuracy, and enhance drug development for complex diseases.